PROJECT SUMMARY
The emergence and transmission of antimicrobial resistance (AMR) is currently one of the most critical public
health threats. As such there is an urgent need to identify new ways to reduce AMR transmission. In recent
years, several studies have started to reveal the complex relations and interactions between antibiotics,
antimicrobial resistance genes (ARGs) and the human microbiome. The human microbiome plays profound roles
in responding to antibiotic treatment and the transmission of ARGs. The altered microbiome, especially in
children, may have a distinct resistome (the entire ARGs in the microbiome community). Infants and young
children receive frequent antimicrobial courses for common respiratory infections and are thought to spread
ARGs effectively in the community. Otitis media is the most common reason for antimicrobial treatment in
children. The antibiotic treatment that is selected for use in young children may significantly influence AMR
spread in the communities. To date, there are a limited number of prospective, controlled comparative studies
on how selected antibiotics affect the development of antibiotic resistance in the microbiome in young children.
It is not possible to investigate children in an experimental way and expose them to antibiotics without an
indication for the treatment. Non-severe acute otitis media, however, is an excellent clinical model to investigate
the impact of different antimicrobial agents, since clinical guidelines suggest several alternative approaches to
treat children, including watchful waiting without antibiotics. In this study, we will investigate the impact of the
most commonly used antibiotics on the intestinal microbiome, and in particular the resistome in children with
otitis media. The Oulu University study is IRB approved and has started enrolling infants and young children with
non-severe otitis media in a study cohort and plan to finish the enrollment within the first few months of this
project. Children are randomly allocated in four antibiotic treatment groups to compare the impact of amoxicillin,
amoxicillin-clavulanate, azithromycin, or no treatment on the intestinal microbiome and ARGs. We will solicit the
antibiotic exposure during lifetime and collect stool samples before (day 0) and three days after the antibiotic
course (day 10). We will apply quantitative PCR, 16S rDNA and metagenomic sequencing on different platforms
to characterize the microbiome and resistome over time. De novo genome assembly based on Oxford Nanopore
long reads technology, combined with high depth Illumina sequencing will reveal the details of ARGs and gene
variants between species, and between microbiome communities, and show us novel mobile elements
containing ARGs, which may be potentially transferred horizontally between species. We will apply machine
learning approaches to quantitatively study how each bacterial species responds to and survives under antibiotic
exposure, by analyzing genomic variants in ARGs, changes in three dimensional structure of the key ARGs,
ARG network and pathways.
